Ipratropium bromide

异丙托溴铵

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameIpratropium bromide
Drug Alias Namebromure d'ipratropium溴化异丙基阿托品溴化异丙托品ipratropii bromidum异丙溴托铵 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptor
Therapy Area/IndicationsDepressionEmphysemaParkinson Disease +[14] 
Global Approved IndicationsEmphysemaPulmonary Disease, Chronic ObstructiveAsthma +[4] 
Approved Indications in ChinaEmphysemaPulmonary Disease, Chronic ObstructiveBronchitis, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date1986/12/29
Country/TerritoryCanadaUnited StatesTunisia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesCook Children'S Health Care SystemChina Resources Double-Crane Pharmaceutical Co LtdBeijing Haiderun Pharmaceutical Co Ltd
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgUniversity Of MonastirUniversity At Buffalo +[6] 
Active IndicationsEmphysemaDyspneaPulmonary Disease, Chronic Obstructive +[5] 
Inactive IndicationsDepressionParkinson DiseaseRhinitis, Allergic, Seasonal +[9] 

Other Information

ATC CodeR01AX03R03BB01
Related LinksDrugBankKEGG